Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Pasteur and WRAIR to develop new Zika vaccine

Sanofi Pasteur and WRAIR to develop new Zika vaccine

6th July 2016

Sanofi Pasteur is partnering with the Walter Reed Army Institute of Research (WRAIR) to develop a new Zika vaccine candidate.

Under the terms of the cooperative research and development agreement, WRAIR will transfer its Zika purified inactivated virus (ZPIV) vaccine technology to Sanofi Pasteur,  a move that could lead to a broader collaboration with the US government.

WRAIR will share data related to the development of immunologic assays to measure neutralising antibody responses following natural infection and vaccination with ZPIV, as well as biologic samples generated from primate studies and human safety and immunogenicity trials.

Sanofi Pasteur, meanwhile, will produce clinical material to support phase II testing, optimisation of the upstream process to improve production yields, and characterisation of the vaccine product, with the firm overseeing clinical development and regulatory strategy.

David Loew, executive vice-president and head of Sanofi Pasteur, said: "In addition to exploring our own vaccine technology used in our new dengue fever vaccine, we are looking at other pathways to get a Zika vaccine into the clinic as soon as possible."

It is hoped that this collaboration will yield a viable vaccine candidate to help tackle the current spread of Zika worldwide.ADNFCR-8000103-ID-801821384-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.